To include your compound in the COVID-19 Resource Center, submit it here.

Arbutus scuttles lead HBV capsid inhibitor program

Arbutus scrapped plans to start a combination trial next year due to the emergence of a safety signal in two healthy volunteers in a Phase I study of

Read the full 287 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE